Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Radiopharmaceuticals for bone lesions - Imaging and therapy in clinical practice
Autore:
Pauwels, EKJ; Stokkel, MPM;
Indirizzi:
Leiden Univ, Ctr Med, Div Nucl Med, Dept Radiol, NL-2300 RC Leiden, Netherlands Leiden Univ Leiden Netherlands NL-2300 RC NL-2300 RC Leiden, Netherlands
Titolo Testata:
QUARTERLY JOURNAL OF NUCLEAR MEDICINE
fascicolo: 1, volume: 45, anno: 2001,
pagine: 18 - 26
SICI:
1125-0135(200103)45:1<18:RFBL-I>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
PAINFUL OSSEOUS METASTASES; SR-89 THERAPY; STRONTIUM KINETICS; TISSUE UPTAKE; PALLIATION; TC-99M; CANCER; AUTORADIOGRAPHY; PYROPHOSPHATE; DIPHOSPHONATE;
Keywords:
bone neoplasms radionuclide imaging; palliative care; bone diseases, diagnosis; radiopharmaceuticals; bone neoplasms, secondary; strontium radioisotopes;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
54
Recensione:
Indirizzi per estratti:
Indirizzo: Pauwels, EKJ Leiden Univ, Ctr Med, Div Nucl Med, Dept Radiol, C4-Q,POB 9600, NL-2300 RCLeiden, Netherlands Leiden Univ C4-Q,POB 9600 Leiden Netherlands NL-2300 RC ands
Citazione:
E.K.J. Pauwels e M.P.M. Stokkel, "Radiopharmaceuticals for bone lesions - Imaging and therapy in clinical practice", Q J NUCL M, 45(1), 2001, pp. 18-26

Abstract

Bone scintigraphy continues to be one of the most commonly performed procedures in nuclear medicine. The radionuclide bone scan remains an excellent modality to detect metastatic disease in patients suffering from primary malignancies. This article reviews a number of aspects of bone scintigraphy such as bone physiology, radiopharmaceuticals and uptake mechanisms. As Tc-99m labelled bis(di)phosphonates are the most frequently used this articke is centred around these imaging agents. In addition to diagnostic bone scintigraphy the use of various bone seeking agents has been extended to the palliative treatment of bone metastases. In this context the radiobiological characteristics of various radionuclides as Sr-89, P-32, Sm-153, Re-186 and Sn-117 is elucidated. In addition, the clinical efficacy for pain killing of these radionuclides is elucidated on the basis of the radiation properties of these agents. It is concluded that Sr-89 and Re-186 are presently the radionuclides of choice. The latter agent has a slight advantage as its imaging photons enable individual dosimetry, resulting in an optimosed application scheme.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 10:32:37